Remdesivir

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir in Participants with Moderate COVID-19 Compared to Standard of Care Treatment

This trial evaluated the efficacy of Remdesivir in patients with moderate COVID-19.

 

Primary objective: To evaluate the efficacy of 2 Remdesivir regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11 

 

Type of studyInterventionalRCT, Phase 3  

 

Treatment testedRemdesivir 

 

Countries: France, Germany, Honk Kong, Italy, The Netherlands, South Korea, Singapore, Switzerland, Spain, Taiwan, UK, USA

 

Number of sitesN/A 

 

Sample size1,600 

 

Study participants:  Adults, confirmed PCR, Hospitalized, Radiographic evidence of pulmonary infiltrates, SpO2 >94% 

 

Study status Completed

 

Study documents

 

More information

 

 

Last modified: September 2020

 

Disclaimer
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.